Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human clinical trial of coronavirus neutralisng antibodies

Trial Profile

A first in human clinical trial of coronavirus neutralisng antibodies

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2020

At a glance

  • Drugs Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua University (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 03 Apr 2020 New trial record
    • 31 Mar 2020 According to a Tsinghua University media release, this study is planned for third quarter this year.

Trial Overview

Purpose

This study will evaluate coronavirus neutralisng antibodies for the treatment and prevention of COVID-19 infections.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention, treatment -

Subjects

  • Subject Type patients
  • Sex not stated

Trial Details

Organisations

  • Affiliations Brii Biosciences

Trial Dates

  • Initiation Dates

    Planned : 01 Jul 2020

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location Unknown
  • Focus Adverse reactions; First in man

Interventions

Drugs Route Formulation
Coronavirus neutralising antibodies 3rd Peoples Hospital of Shenzhen/Brii Biosciences/Tsinghua UniversityPrimary Drug Parenteral
-

Coronavirus neutralisng antibodies

Trial History

Event Date Event Type Comment
03 Apr 2020 New trial record New trial record Updated 03 Apr 2020
31 Mar 2020 Other trial event According to a Tsinghua University media release, this study is planned for third quarter this year. Updated 03 Apr 2020

References

  1. Tsinghua University. Tsinghua University, 3rd Peoples Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19. Media-Rel 2020;.

    Media Release
Back to top